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Results: Results	 demonstrated	 the	 excellent	 interexperiment	 precision	 of	 the	
ST	Genesia	 and	 confirmed	 that	 the	 use	 of	 a	 reference	 plasma	 helps	 reducing	 the	
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1  | INTRODUC TION
Thrombin	 generation	 has	 been	 used	 since	 the	 early	 1950s.1	 At	
the	start,	whole	blood	or	plasma	was	supplemented	with	triggers	
such	as	 tissue	 factor	or	activator	of	 the	 intrinsic	pathway	of	 the	
coagulation	 combined	 with	 calcium	 chloride	 to	 initiate	 coagula-
tion.	 Thrombin	 generation	 was	 then	 evaluated	 by	 sampling	 the	
clotting	 mixture	 at	 regular	 intervals	 into	 a	 test	 tube	 containing	
fibrinogen.	The	clotting	times	were	then	recorded	and	the	quan-
tity	of	 thrombin	generated	was	derived	 from	a	calibration	curve	




the	 parameters	 stemming	 from	 the	 thrombogram.3	 Finally,	 the	




have	 laid	 the	 groundwork	 for	 what	 is	 now	 known	 as	 calibrated	
automated	 thrombogram	 (CAT).4	 Currently,	 different	 solutions	




CAT	 (Diagnostica	 Stago).	 These	 last	 two	 both	 use	 a	 fluorogenic	
substrate5;	however,	some	limitations	have	been	highlighted,	such	
as	the	lack	of	established	standardization	of	the	methods	and	re-
agents,	 and	missing	 quality	 controls.	 In	 addition,	 batch-to-batch	



























and to enter the clinical laboratory.




















•	 Normal	 range	 of	 the	 STG-DrugScreen	 application	 has	
been	assessed	in	healthy	subjects.
•	 The	 ST	 Genesia	 may	 facilitate	 the	 implementation	 of	
thrombin	generation	in	the	routine	laboratory.
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patients’	plasma	and	to	evaluate	the	 intensity	of	the	treatment12‒19 
therefore,	 Diagnostica	 Stago	 aimed	 at	 developing	 a	 kit	 for	 the	 as-
sessment	 of	 thrombin	 generation	 in	 anticoagulated	 patients,	 the	
































2.2 | Normal and targeted population and samples
Six	healthy	 individuals	 and	23	 samples	 from	patients	 treated	with	
an	anticoagulant	have	been	included	in	the	stability	study	(apixaban	
n	 =	 4;	 dabigatran	 n	 =	 3;	 low-molecular-weight	 heparins	 [LMWH]	
n	=	5;	 rivaroxaban	n	=	5;	 vitamin	K	 antagonists	 [VKA]	n	=	6).	 For	
patients	 on	 apixaban,	 dabigatran,	 and	 rivaroxaban,	 plasma	 had	 to	
be	taken	at	peak	 (i.e.,	between	30	minutes	and	4	hours	after	drug	
intake)	 to	 obtain	 the	 highest	 effect	 on	 thrombin	 generation.	 For	
patients	under	LMWH,	 the	blood	had	 to	be	 taken	between	1	and	
6	hours	after	the	administration	while	for	patients	under	VKA,	the	
targeted	international	normalized	ratio	(INR)	was	between	2	and	3.









2.4 | Assessment of anticoagulant activity with 
specific tests
For	 patients	 on	 apixaban,	 rivaroxaban,	 and	 LMWH,	 the	 estimated	
concentrations	 or	 the	 anti-Xa	 activity	 have	 been	 measured	 using	
the	 STA-Liquid	 Anti-Xa	 (Diagnostica	 Stago)	 and	 the	 correspond-
ing	 calibrators	 and	 controls	 according	 to	 the	 recommendations	 of	
the	manufacturer	 on	 an	 STA-R	Max	 analyzer	 (Diagnostica	 Stago).	
For	 dabigatran	 samples,	 the	 estimated	 dabigatran	 plasma	 concen-
trations	 have	 been	 measured	 using	 the	 STA-ECA	 II	 (Diagnostica	
Stago)	with	the	corresponding	calibrators	and	controls.	For	VKA	pa-
tients,	 the	 INRs	have	been	measured	with	 the	STA–Neoplastine	R	
(Diagnostica	Stago)	according	to	the	recommendations	of	the	manu-
facturer.	For	healthy	individuals,	the	prothrombin	time	(PT)	and	the	




2.5 | Determination of the precision of the ST 
Genesia in its STG‐DrugScreen application
Each	day	of	testing	(n	=	97),	a	new	calibration	is	set	and	the	quality	
controls	(two	levels)	and	the	reference	plasma	are	assessed.	During	









2.6 | Determination of the stability after 




















plotted	 vs	 time	 for	 each	 time	 point.	 The	 regression	 line	 of	 this	








interval	 (CI)	 of	 the	 linear	 regression	with	 the	 adjusted	 rejection	
limit.	If	there	is	no	interception,	the	maximal	duration	limit	is	de-
fined	 as	 the	 last	 point	 of	measurement	 (see	 the	Results	 section	
and	Figures	1	and	2	for	graphical	representation).





















Y = 0.005 + 0.414 * X















Y = –10.310 + 3.749 * X















Y = –3.735 – 1.596 * X















Y = –4.123 + 2.453 * X




















Y = –16.530 + 10.950 * X





performed.	 If	 the	 population	had	not	 a	 normal	 distribution,	 then	
the	paired	results	were	compared	using	a	Wilcoxon	matched	rank-





3.1 | Thrombin generation values of the reference 
plasma and controls and precision of the ST‐Genesia
The	within-batch	variability	was	always	below	the	between-batches	
relative	 differences,	 except	 for	 the	 normalized	 ETP	 of	 the	 STG-
QualiTest	Low	DS	(Table	1).	The	within-batch	variability	was	always	
below	6%.	All	results	are	summarized	in	Table	1.
3.2 | Impact on freezing on thrombin 
generation parameters
On	 the	 total	 cohort	 (n	=	29	 samples),	 Shapiro-Wilk	 normality	 test	
showed	normal	distribution	 for	 the	 lag	 time	and	 the	ETP	parame-
ters,	whereas	the	normality	failed	for	the	peak	height	and	the	time	
to	peak.	This	means	that,	according	to	the	statistical	analysis	plan,	
a t	 test	 for	paired	samples	was	used	for	 the	 lag	time	and	the	ETP,	
whereas	a	Wilcoxon	matched	rank-signed	test	was	used	for	the	peak	
height	 and	 the	 time-to-peak.	 Because	 of	 a	 small	 sample	 size,	 the	
Wilcoxon	matched	rank-signed	test	was	used	when	the	results	were	
stratified	by	treatment	(Table	2).
Wilcoxon	 matched	 rank-signed	 test	 revealed	 no	 significant	
difference	 between	 the	 two	 conditions	 on	 lag	 time,	 peak	 height,	
and	ETP,	whereas	 the	 time-to-peak	was	 impaired	 (mean	of	 differ-
ence	 =	 −0.15	 minutes).	 When	 results	 are	 analyzed	 by	 treatment,	
there	is	no	significant	difference	between	fresh	and	frozen	plasma	
(Table	2).
3.3 | Stability of the plasma samples once 




(Figure	1)	 and	 the	maximal	 storage	duration	was	defined	 as	 the	
latest	point	assessed	in	this	study	(i.e.,	11	months	for	healthy	vol-
unteers	and	10	months	for	anticoagulated	patients).	Stratification	





tion	 for	 this	 parameter	 was	 also	 defined	 at	 the	 latest	 point	 as-
sessed	 in	 this	 study	 (i.e.,	 11	 months).	 Again,	 stratification	 by	
treatment	did	not	provide	different	results	(Table	3).	For	the	peak	
height,	 the	 adjusted	 RLs	 were	 −110%	 to	 90%,	 the	 slope	 of	 lin-
ear	regression	was	equal	to	3.749	(95%	CI,	−1.675	to	5.822).	The	
95%	 CI	 of	 the	 linear	 regression	 did	 not	 cross	 the	 adjusted	 RLs	
(Figure	 1)	 and	 the	 maximal	 storage	 duration	 for	 this	 parameter	
was	 also	 defined	 at	 the	 latest	 point	 assessed	 in	 this	 study	 (i.e.,	






tion	 for	 this	parameter	was	defined	at	 the	 latest	point	 assessed	
in	this	study	(i.e.,	11	months).	Stratification	by	treatment	did	not	
provide	different	results	(Table	3).
3.4 | Thrombin generation in the normal and 
targeted population
The	 reference	 values	 obtained	 in	 the	 healthy	 population	 re-
vealed	thrombin	generation	values	close	to	the	value	of	the	ref-
erence	plasma	 (Table	4).	Screening	coagulation	 testing,	namely	
the	 PT	 and	 aPTT,	 were	 normal	 in	 all	 healthy	 individuals	 (PT:	
mean	 =	 13.7	 ±	 0.7	 seconds;	 min-max	 range	 =	 11.9-15.10	 sec-










subjects	 at	 the	 lowest	 concentration	 observed	 (i.e.,	 51	 ng/mL)	
(Table	 5).	 For	 LMWH,	 the	 peak	 anti-Xa	 effect	 were	 between	
0.35	IU/mL	and	1.37	IU/mL.	All	thrombin	generation	parameters	
were	 affected.	 In	 the	 patient	 with	 the	 highest	 exposure	 (i.e.,	
1.37	IU/mL),	the	peak	height	and	the	ETP	were	highly	affected	
(8%	 and	 14%	 the	 value	 of	 the	 reference	 plasma,	 respectively)	
(Table	 5).	 For	 rivaroxaban,	 the	 peak	 plasma	 concentrations	
were	 between	 197	 and	 300	 ng/mL.	 The	most	 affected	 throm-
bin	generation	parameters	were	the	peak	height	and	the	time	to	











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TA B L E  2   Impact	of	freezing	on	thrombin	generation	parameters
Fresh (D0) vs frozen 
(D1) Passed normality testing?
Mean difference 
(D1‐D0)
Wilcoxon matched‐pairs signed rank test or 
paired t test (P value) Significant?
 All	results	(n	=	29)
Lag	timea  Yesa  −0.08	min 0.7179a  No
Peak	height No 3.29	nmol/L 0.096 No
Time-to-peak No −0.15	min 0.020 Yes
ETPa  Yesa  1	nmol/L/min 0.9702a  No
 Apixaban	(n	=	4)
Lag	time N	too	small −0.09	min 0.375 No
Peak	height  19.38	nmol/L 0.250 No
Time-to-peak  −0.24	min 0.250 No
ETP  −4	nmol/L/min 0.875 No
 Dabigatran	(n	=	3)
Lag	time N	too	small −0.25	min 0.250 No
Peak	height  7.53	nmol/L 0.500 No
Time-to-peak  −0.23	min 0.500 No
ETP  27	nmol/L/min 0.250 No
 Healthy	(n	=	6)
Lag	time N	too	small −0.02	min >0.999 No
Peak	height  −20.17	nmol/L 0.688 No
Time-to-peak  −0.03	min >0.999 No
ETP  −116	nmol/L/min 0.438 No
 LMWH	(n	=	5)
Lag	time N	too	small −0.00	min >0.999 No
Peak	height  2.78	nmol/L 0.625 No
Time-to-peak  −0.09	min 0.474 No
ETP  28	nmol/L/min 0.313 No
 Rivaroxaban	(n	=	5)
Lag	time N	too	small −0.21	min 0.063 No
Peak	height  14.77	nmol/L 0.125 No
Time-to-peak  −0.53	min 0.063 No
ETP  79	nmol/L/min 0.188 No
 Vitamin	K	antagonists	(n	=	6)
Lag	time N	too	small −0.02	min 0.750 No
Peak	height  4.79	nmol/L 0.313 No
Time-to-peak  −0.04	min 0.313 No














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1284  |     DOUXFILS et aL.
the	 routine	 practice.2	 By	 providing	 a	 complete	 kit	 of	 reagent	 and	
controls,	the	STG-DrugScreen	application	of	the	ST	Genesia	simpli-












data	 from	the	daily	calibration	and	 the	value	of	 the	 two	 levels	of	
control	and	reference	plasma	(i.e.,	the	STG-QualiTest	Low	DS	and	
STG-QualiTest	 Norm	 DS	 and	 STG-RefPlasma	 DS,	 respectively)	
over	 a	 15-month	period.	 Two	batches	of	 reagents	were	provided	
by	the	manufacturer	during	the	course	of	this	study.	Main	results	
revealed	 that	 the	 coefficient	 of	 variation	 of	 the	 different	 param-
eters	were	always	<10%	and	for	 the	majority	of	 these	results	 the	
CV	was	 even	 <5%	 (Table	 1).	 As	 previously	 reported,10	 this	 study	
also	demonstrates	that	the	use	of	a	reference	plasma	reduced	the	
interexperiment	 variability.	 Regarding	 the	 stability	 of	 the	 sam-
ples,	our	results	demonstrate	that	freezing	has	no	impact	on	most	
thrombin	generation	parameters	except	the	time	to	peak,	especially	









thrombin	generation	assessment	of	 anticoagulant	 treatment21 and 





study.	Only	 trends	 can	 be	 drawn	 on	 the	 overall	 effect	 of	 the	 dif-
ferent	anticoagulant	agents;	further	work	is	necessary	to	define	the	




plasma	 to	 reduce	 the	 interlaboratory	 variability.6,7,9,10	The	 choice	
of	 providing	 a	 reference	 plasma	 within	 the	 STG-DrugScreen	 kit	
agrees	with	the	literature	because	it	has	been	reported	that	the	use	
of	local	plasma	(i.e.,	a	reference	plasma	performed	at	the	laboratory	








strategy	 improves	 the	between-batch	variation.	 In	 this	 study,	we	
report	relative	differences	between	batches	from	0%	to	24%	when	






ity	 than	 frozen	plasma	 from	multiple	preanalytical	 reasons.6,22 In 
any	case,	the	conditions	in	which	these	reference	plasmas	are	pro-
duced	are	probably	 far	 from	the	best	 recommendations	of	blood	
sample	 collection	 for	 thrombin	 generation	 testing	because	 these	
reference	plasmas	have	to	be	produced	on	a	large	scale.	Thus,	one	




package	 insert	 of	 the	STG-DrugScreen	kit,	 an	 assay	 value	of	 the	
reference	plasma	 is	provided	by	 the	manufacturer	 to	correct	 the	
reference	 plasma	 activity.	 The	 results	 of	 this	 study	 demonstrate	
that	this	approach	is	efficient	since	our	healthy	subjects,	collected	
in	 ideal	 conditions	 for	 this	 application,	 were	 close	 to	 100%	 or	 a	
ratio	of	1	depending	on	 the	parameter	 (Table	5).	 In	 addition,	 the	
difference	between	the	two	batches	of	the	STG-RefPlasma	DS	was	





It	 has	 been	 reported	 that	 internal	 quality	 control	 is	 essential	 to	
produce	 consistent	 results	 for	 thrombin	 generation23	 however,	
in	 the	 era	 of	 thrombin	 generation,	 the	 confusion	 between	 internal	
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results	were	always	below	10%	and	for	the	majority	of	the	param-
eters	were	 even	 below	5%.	 These	 interassay	 precision	 results	 are	








4.3 | Impact of freezing and stability of the samples
A	previous	study	evaluating	the	effect	of	preanalytical	parameters	





ity	 of	 thrombin	 generation	 using	 the	 CAT	 system	 for	 the	meas-
urement	of	the	procoagulant	activity	of	circulating	microparticles	
with	 the	 MP-reagent	 from	 Thrombinoscope	 bv,	 a	 reagent	 that	
does	not	contain	tissue	factor	to	trigger	the	coagulation.	There	is	
a	different	setting	than	the	one	assessed	in	this	study	because	the	








Freezing	has	no	effect	on	 the	majority	of	 the	 thrombin	gener-
ation	 parameters	 using	 the	 STG-DrugScreen	 application,	 except	
for	time	to	peak	(Table	2).	Once	frozen,	plasma	samples	are	stable	







platelets	 released	PF4	during	 storage	and	 thus	neutralize	heparin.	


















always	below	20%	and	was	below	10%	 for	 the	 lag	 time	and	 the	
time-to-peak.	When	 comparing	with	 the	 results	 obtained	 in	 pa-








4.5 | Usefulness of thrombin generation to assess 
anticoagulated patients
Tailoring	drug	dosages	to	fit	the	needs	of	 individual	patients	could	






trations.28	 In	 addition	 to	 considering	 the	 interindividual	 response	
to	an	antithrombotic	drug,	thrombin	generation	testing	is	also	able	
to	 explore	 in	 more	 detail	 the	 effect	 of	 anticoagulants	 on	 the	 co-
agulation	process.	Namely,	depending	the	type	of	drug,	our	results	











cation	 for	 patient	 care.36	 This	 is	 particularly	 important	 because	 it	
may	help	in	adjusting	the	dose	of	prothrombin	complex	concentrate	
to	administer.37	The	ST	Genesia	will	provide	a	step	forward	to	this	
aim	 in	allowing	 thrombin	generation	 to	be	done	routinely	with	 re-
duced	interexperiments	and	interlaboratory	variations.	In	this	way,	
it	will	be	easier	to	recruit	patients,	design	multicenter	studies,	and	
provide	data	 for	 the	establishment	of	 reliable	and	evidence-based	
thresholds.
1286  |     DOUXFILS et aL.
5  | CONCLUSIONS
This	 is	 the	 first	 study	 presenting	 performance	 data	 of	 the	 ST	
Genesia,	 a	new	benchtop	analyzer	 for	 thrombin	generation	 test-
ing.	 The	 study	 aimed	 at	 evaluating	 the	 performances	 of	 the	
STG-DrugScreen	 application,	 a	 kit	 of	 reagents	 designed	 for	 the	
quantitative	 determination	 of	 thrombin	 generation	 in	 plasma	
from	patients	 treated	with	an	anticoagulant.	Results	 revealed	an	
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